Technical Analysis for GNFT - GENFIT S.A.

Grade Last Price % Change Price Change
F 4.31 1.10% 0.05
GNFT closed up 1.1 percent on Wednesday, November 20, 2024, on 12 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Flat Down Down

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Fell Below 200 DMA Bearish 1.10%
Narrow Range Bar Range Contraction 1.10%
Lower Bollinger Band Walk Weakness 1.10%
Wide Bands Range Expansion 1.10%
Below Lower BB Weakness 1.10%

   Recent Intraday Alerts

Alert Time
Rose Above Lower Bollinger Band about 18 hours ago
Up 1% about 18 hours ago
Fell Below 200 DMA 1 day ago
Fell Below Previous Day's Low 1 day ago
Down 2 % 1 day ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

GENFIT S.A. Description

GENFIT is a biopharmaceutical company focused on discovering and developing drug candidates and diagnostic solutions targeting liver diseases, in particular those of metabolic origin, and hepatobiliary diseases. GENFIT concentrates its R&D efforts in areas of high unmet medical needs corresponding to a lack of approved treatments. GENFIT’s lead proprietary compound, elafibranor, is a drug candidate currently being evaluated in one of the most advanced Phase 3 studies worldwide (RESOLVE-IT) in nonalcoholic steatohepatitis, or NASH, considered by regulatory authorities as a medical emergency because it is silent, with potentially severe consequences, and with a prevalence on the rise. Elafibranor has also obtained positive preliminary results in a Phase 2 clinical trial in primary biliary cholangitis, or PBC, a severe chronic liver disease. As part of its comprehensive approach to clinical management of NASH patients, GENFIT is conducting an ambitious discovery and development program aimed at providing patients and physicians with a blood-based test for the diagnosis of NASH, i.e. non-invasive and easy-to-access. With facilities in Lille and Paris, France, and Cambridge, MA (USA), the Company has approximately 150 employees.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Alcohol Autoimmune Disease Hepatitis Steatohepatitis Non Alcoholic Fatty Liver Disease Liver Disease Hepatology Liver Diagnostic Solutions Primary Biliary Cholangitis Chronic Liver Disease Clinical Management

Is GNFT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 6.4229
52 Week Low 3.08
Average Volume 16,284
200-Day Moving Average 4.33
50-Day Moving Average 5.31
20-Day Moving Average 5.27
10-Day Moving Average 4.86
Average True Range 0.24
RSI (14) 27.54
ADX 32.41
+DI 11.45
-DI 43.07
Chandelier Exit (Long, 3 ATRs) 5.31
Chandelier Exit (Short, 3 ATRs) 4.98
Upper Bollinger Bands 6.37
Lower Bollinger Band 4.17
Percent B (%b) 0.06
BandWidth 41.62
MACD Line -0.30
MACD Signal Line -0.14
MACD Histogram -0.1656
Fundamentals Value
Market Cap 214.79 Million
Num Shares 49.8 Million
EPS -0.84
Price-to-Earnings (P/E) Ratio -5.13
Price-to-Sales 6.39
Price-to-Book 2.28
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.35
Resistance 3 (R3) 4.35 4.33 4.35
Resistance 2 (R2) 4.33 4.32 4.33 4.34
Resistance 1 (R1) 4.32 4.31 4.32 4.32 4.34
Pivot Point 4.30 4.30 4.30 4.30 4.30
Support 1 (S1) 4.29 4.29 4.30 4.30 4.28
Support 2 (S2) 4.27 4.28 4.27 4.28
Support 3 (S3) 4.26 4.27 4.27
Support 4 (S4) 4.27